市场调查报告书
商品编码
1576500
数位生物製造市场规模、占有率、预测和趋势分析:按产品(软体/硬体)、按功能(产品设计/分析、自动化)、按应用(MAB、蛋白质、疫苗)、按生物工艺- 2031 年之前的世界预测Digital Biomanufacturing Market Size, Share, Forecast, & Trends Analysis by Offering (Software Hardware), Functionality (Product Design, Analytics, Automation), Application (MAB, Protein, Vaccine), and Bioprocess - Global Forecast to 2031 |
数位生物製造市场预计到 2031 年将达到 508.9 亿美元,2024 年至 2031 年复合年增长率为 13.3%。
经过广泛的二次和初步研究以及对市场情景的详细分析,本报告对关键行业的推动因素、阻碍因素、课题和机会进行了分析。数位生物製造市场的成长是由生物製品需求的增加、主要公司增加生物製药工厂产能、对製程优化的需求不断增长、对品质标准和监管合规性的日益关注以及对研发管道的强劲需求推动的。然而,技术实施的高成本以及生物製药开发和製造过程的复杂性限制了该市场的成长。
此外,工业 4.0 技术的引入、先进数据分析工具的可用性以及向生物製程 4.0 的转变预计将为市场成长创造机会。然而,实施下游製程分析技术(PAT)的复杂性以及生物製药製造所需的密集资本要求是数位生物製造市场的主要课题。
(註:包含前5名公司的SWOT分析)
Digital Biomanufacturing Market Size, Share, Forecast, & Trends Analysis by Offering (Software [PAT, MES, Digital Twin] Hardware) Functionality (Product Design, Analytics, Automation) Application (MAB, Protein, Vaccine) Bioprocess-Global Forecast to 2031
The digital biomanufacturing market is projected to reach $50.89 billion by 2031, at a CAGR of 13.3% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the digital biomanufacturing market is driven by growing demand for biologics, capacity expansions of biopharmaceutical plants by key players, increased need for process optimization, increased focus on quality standards & regulatory compliance, strong R&D pipeline for biopharmaceuticals, and rising focus on continuous bioprocessing. However, the high cost of technology deployment and the complex development and manufacturing process of biopharmaceuticals are restraining the growth of this market.
Furthermore, the introduction of industry 4.0 technologies, availability of advanced data analysis tools, and shift towards bioprocessing 4.0 are expected to generate market growth opportunities. However, complexities in process analytical technology (PAT) implementation for downstream processes and intensive capital requirements for biopharmaceutical production are major challenges in the digital biomanufacturing market.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the digital biomanufacturing market are GE Healthcare Technologies Inc. (U.S.), Siemens Xcelerator (Subsidiary of Siemens) (Germany), Cytiva (a subsidiary of Danaher Corporation) (U.S.), ABB Ltd. (Switzerland), Sanofi S.A. (France), Emerson Electric co. (U.S.), Honeywell International Inc. (U.S.), SAP SE (Germany), OVO Biomanufacturing. (U.S.), Schneider Electric SE (France), Dassault Systems (France), Oracle Corporation (U.S.), and 3M (U.S.).
Among all the offerings studied in this report, the software segment is expected to account for the largest share of 74.4% of the digital biomanufacturing market. The rising demand for process optimization coupled with the advantages of software in designing, planning, and manufacturing of drugs or biologics support the large share of this segment.
Among all the functionalities studied in this report, in 2024, the process optimization & analytics segment is expected to account for the largest share of the digital biomanufacturing market. Process optimization and analytics help in improving the manufacturing process by streamlining operating procedures. This involves real-time monitoring and analysis of the activities, which helps the organization in finding bugs in the process or deciding the area of improvement. Moreover, this helps in increasing the efficiency of manufacturing equipment and makes the biomanufacturing process efficient.
Among all the bioprocesses studied in this report, in 2024, the downstream bioprocess segment is expected to account for the largest share of the digital biomanufacturing market. Downstream bioprocesses are considered a complex process in nature that requires continuous monitoring. Digital biomanufacturing software helps in improving and maintaining the workflow of these bioprocesses. This also improves the quality of products. Moreover, the use of predictive technology in the software helps reduce the future complexities associated with downstream bioprocesses, which results in reducing extra costs or future loss. Such factors are driving the growth of the market.
Among all the applications studied in this report, in 2024, the monoclonal antibodies segment is expected to account for the largest share of 48.6% of the digital biomanufacturing market. The availability of funding for monoclonal antibody research and development, approvals for monoclonal antibodies, and increasing production capacity of monoclonal antibody manufacturing plants are contributing to the largest share of the segment.
Among all the end users studied in this report, in 2024, the biopharmaceutical companies segment is expected to account for the largest share of the digital biomanufacturing market. Initiatives focused on improving the adoption of biopharmaceuticals, patent expiration of biologics, and increasing awareness of biopharmaceuticals among physicians are supporting the largest share of the market.
An in-depth analysis of the geographical scenario of the digital biomanufacturing printing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Among all the geographies studied in this report, in 2024, North America is expected to account for the largest share of the digital biomanufacturing market. The largest share is attributed to the developed healthcare industry & infrastructure, the presence of major key players, and supportive initiatives focused on improving the adoption of biopharmaceuticals.
Digital Biomanufacturing Market Assessment-by Offering
Digital Biomanufacturing Market Assessment-by Functionality
Note: Other functionalities include Quality management, predictive maintenance, and data storage.
Digital Biomanufacturing Market Assessment-by Bioprocess
Digital Biomanufacturing Market Assessment-by Application
Digital Biomanufacturing Market Assessment-by End User
Digital Biomanufacturing Market Assessment -by Geography
(Note: SWOT analysis of the top 5 companies will be provided.)